ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B

Liu, Zhihong; Jin, Qinglong; Zhang, Yuexin; Gong, Guozhong; Wu, Guicheng; Yao, Lvfeng; Wen, Xiaofeng; Gao, Zhiliang; Huang, Yan; Yang, Daokun; Chen, Enqiang; Mao, Qing; Lin, Shide; Shang, Jia; Gong, Huanyu; Zhong, Lihua; Yin, Huafa; Wang, Fengmei; Hu, Peng; Xiao, Ling; Li, Chuan; Wu, Qiong; Sun, Chang'an; Niu, Junqi*; Hou, Jinlin*安徽医科大学; 吉林大学; 南方医科大学; 哈尔滨医科大学; 四川大学; 中山大学; 重庆大学; 1
Alimentary Pharmacology and Therapeutics2021-11DOI: 10.1111/apt.16611
9被引13阅读
引用收藏
分享

摘要

Background Tenofovir amibufenamide (TMF) can provide more efficient delivery than tenofovir disoproxil fumarate (TDF). Aim To compare the efficacy and safety of TMF and TDF for 48 weeks in patients with chronic hepatitis B (CHB). Methods We performed a randomised, double-blind, non-inferiority study at 49 sites in China. Patients with CHB were assigned (2:1) to receive either 25 mg TMF or 300 mg TDF with matching placebo. The primary efficacy endpoint was the proportion of patients with hepatitis B virus (HBV) DNA less than 20 IU/mL at week 48. We also assessed safety, particularly bone, renal and metabolic abnormalities. Results We randomised 1002 eligible patients. The baseline characteristics were well balanced between groups. After a median 48 weeks of treatment, the non-inferiority criterion was met in all analysis sets. In the HBeAg-positive population, 50.2% of patients receiving TMF and 53.7% receiving TDF achieved HBV DNA less than 20 IU/mL. In the HBeAg-negative population, 88.9% and 87.8%, respectively, achieved HBV DNA less than 20 IU/mL in the TMF and TDF groups. Patients receiving TMF had significantly less decrease in bone mineral density at both hip (P < 0.001) and spine (P < 0.001), and a smaller increase in serum creatinine at week 48 (P < 0.05). Other safety results were similar between groups. Conclusion TMF was non-inferior to TDF in terms of anti-HBV efficacy and showed better bone and renal safety. (NCT03903796).

学科与关键词

关键词
BONE-MINERAL DENSITYADEFOVIR DIPIVOXILENTECAVIR THERAPYFANCONI SYNDROMEVIRUS INFECTIONDOUBLE-BLINDALAFENAMIDELAMIVUDINECIRRHOSISANALOGS
相关
加载中…
  • 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
    Liu, Zhihong; Jin, Qinglong; Zhang, Yuexin; Gong, Guozhong; Wu, Guicheng; Yao, Lvfeng; Wen, Xiaofeng; Gao, Zhiliang; Huang, Yan; Yang, Daokun; Chen, Enqiang; Mao, Qing; Lin, Shide; Shang, Jia; Gong, Huanyu; Zhong, Lihua; Yin, Huafa; Wang, Fengmei; Hu, Peng; Wu, Qiong; Pan, Chao; Jia, Wen; Li, Chuan; Sun, Chang'a; Niu, Junqi*; Hou, Jinlin*Journal of Clinical and Translational Hepatology, 2023, 11(3): 649-660.被引 3
  • 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
    Hou, Jinlin*; Ning, Qin*; Duan, Zhongping; Chen, You; Xie, Qing; Wang, Fu-Sheng; Zhang, Lunli; Wu, Shanming; Tang, Hong; Li, Jun; Lin, Feng; Yang, Yongfeng; Gong, Guozhong; Flaherty, John F.; Gaggar, Anuj; Mo, Shuyuan; Cheng, Cong; Camus, Gregory; Chen, Chengwei; Huang, Yan; Jia, Jidong; Zhang, MingxiangJournal of Clinical and Translational Hepatology, 2021, 9(3): 324-334.被引 17
  • Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
    Liang, Xieer; Xie, Qing; Shang, Jia; Tang, Hong; Xu, Min; Meng, Qinghua; Zhang, Jiming; Gao, Pujun; Sheng, Jifang; Wang, Hao; Jia, Jidong; Wang, Guiqiang; Wu, Shunquan; Ping, Jingna; Hou, Jinlin*Journal of Gastroenterology and Hepatology, 2022, 37(3): 471-479.
查看全部 →

发表信息

论文状态
公开发表
期刊
Alimentary Pharmacology and Therapeutics
发表日期
2021-11
卷期
第 54 卷, 第 9 期
页码
1134-1149
DOI
10.1111/apt.16611
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Hansoh Pharmacy Co.

作者

  • L

    Liu, Zhihong (第一作者)

    southern med univ

  • J

    Jin, Qinglong

    jilin univ

查看全部 25 位作者收起作者
  • Z

    Zhang, Yuexin

    1 · xinjiang med univ

  • G

    Gong, Guozhong

    2

  • W

    Wu, Guicheng

    chongqing univ

  • Y

    Yao, Lvfeng

    fujian med univ

  • W

    Wen, Xiaofeng

    liuzhou peoples hosp

  • G

    Gao, Zhiliang

    zhongshan univ

  • H

    Huang, Yan

  • Y

    Yang, Daokun

    1 · xinxiang med univ

  • C

    Chen, Enqiang

    sichuan univ

  • M

    Mao, Qing

  • L

    Lin, Shide

  • S

    Shang, Jia

    henan prov peoples hosp

  • G

    Gong, Huanyu

  • Z

    Zhong, Lihua

    harbin med univ

  • Y

    Yin, Huafa

    1 · anhui med univ

  • W

    Wang, Fengmei

    tianjin third cent hosp

  • H

    Hu, Peng

    2 · chongqing med univ

  • X

    Xiao, Ling

  • L

    Li, Chuan

  • W

    Wu, Qiong

  • S

    Sun, Chang'an

  • N

    Niu, Junqi (通讯)

    jilin univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417